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ABSTRACT 20 
Vaccination regimes against Infectious bronchitis virus, which are based on a single virus serotype, 21 
often induce insufficient levels of cross-protection against serotypes and two or more antigenically 22 
diverse vaccines are used in attempt to provide broader protection. Amino acid differences in the 23 
surface protein, spike (S), in particular the S1 subunit, are associated with poor cross-protection. 24 
Here, homologous vaccination trials with recombinant IBVs, based on the apathogenic strain, 25 
BeauR, were conducted to elucidate the role of S1 in protection.  A single vaccination of SPF-26 
chickens with rIBV expressing S1 of virulent strains M41 or QX, BeauR-M41(S1) and BeauR-27 
QX(S1), gave incomplete protection against homologous challenge, based on ciliary activity and 28 
clinical signs. There could be conformational issues with the spike if heterologous S1 and S2 are 29 
linked, suggesting a homologous S2 might be essential.  To address this, a homologous 30 
vaccination-challenge trial incorporating rIBVs expressing full spike from M41, BeauR-M41(S), 31 
and S2 subunit from M41, BeauR-M41(S2) was conducted. All chimaeric viruses grew to similar 32 
titres in vitro, induced virus-specific partial protective immunity, evident by cellular infiltrations, 33 
reductions in viral RNA load in the trachea and conjunctiva and higher serum anti-IBV titres. 34 
Collectively, these show that vaccination with rIBVs primed the birds for challenge but the viruses 35 
were cleared rapidly from the mucosal tissues in the head. Chimaeric S1 and S2 viruses did not 36 
protect as effectively as BeauR-M41(S) based on ciliary activity and clinical signs. Booster 37 
vaccinations and a rIBV with improved in vivo replication may improve the levels of protection.  38 
  39 
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IMPORTANCE 40 
Infectious bronchitis virus causes an acute, highly contagious respiratory disease, responsible for 41 
significant economic losses to the poultry industry. Amino acid differences in the surface protein, 42 
spike (S), in particular the S1 subunit, have been associated with poor cross-protection. Available 43 
vaccines give poor cross-protection and rationally designed live attenuated vaccines, based on 44 
apathogenic BeauR, could address these. Here, to determine the role of S1 in protection, a series 45 
of homologous vaccination trials with rIBVs were conducted.  Single vaccinations with chimaeric 46 
rIBVs induced virus-specific partial protective immunity, characterised by reduction in viral load 47 
and serum antibody titres. However, BeauR-M41(S) was the only vaccination to improve the level 48 
of protection against clinical signs and the loss of tracheal ciliary activity. Growth characteristics 49 
show all of the rIBVs replicated in vitro to similar levels. Booster vaccinations and a rIBV with 50 
improved in vivo replication may improve the levels of protection. 51 
 52 
INTRODUCTION 53 
Infectious Bronchitis virus (IBV) is classified as a gammacoronavirus, subfamily Coronavirinae, 54 
order Nidovirales (1).  IBV is responsible for major economic losses to poultry industries 55 
worldwide as a result of poor weight gain, decreased egg production and impaired egg quality.  56 
The effect of IBV on the ciliary activity in the trachea and the immune system may predispose 57 
infected chickens to secondary infections with opportunistic bacteria, which often increases the 58 
mortality rate associated with IBV (2-4).  59 
IBV is an enveloped virus, with a single-stranded, positive sense RNA genome (~28kB), and 60 
encodes four structural proteins: nucleocapsid (N), spike glycoprotein (S), small membrane protein 61 
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envelope (E) and integral membrane protein (M) (5, 6). The major surface protein of IBV, S, is a 62 
type 1 glycoprotein which oligomerises to form trimers (7) and is thought to be the main inducer 63 
of protective immunity (8-12). The S protein is proteolytically cleaved into two subunits, the N-64 
terminal subunit S1 (approx. 500-550 amino acids, 90-kDa) and the C-terminal subunit, S2 (630 65 
amino acids, 84-kDa), which contains the transmembrane domain.  The S1 subunit plays a critical 66 
role in binding to cellular receptors as it contains the receptor binding domain (13, 14), determines 67 
the virus serotype and is responsible for the induction of neutralising antibodies (14-16).  Multiple 68 
studies have shown that recombinant S1 expressed in adenovirus and Newcastle Disease Virus 69 
vectors can induce a certain level of protection in specified-pathogen free (SPF) chickens against 70 
challenge with wild-type virus (11, 17, 18).  71 
Vaccine programmes against IBV often include a combination of live or inactivated vaccines 72 
which are based on several dominant field serotypes of the virus. The current vaccines often induce 73 
insufficient cross-protection, and combinations of antigenically different vaccines are used in an 74 
effort to improve levels of protection (19).  Alongside this, with the continual emergence of new 75 
field strains the control of IBV is persistently a significant problem to the poultry industry.  76 
A reverse genetics system based on the avirulent strain of IBV Beaudette has been developed (20, 77 
21). This system has many potential applications, including; to enhance our understanding of the 78 
role of individual genes in pathogenicity and to lead to a new generation of rationally designed 79 
live attenuated vaccines (20). Previous work using the reverse genetics approach demonstrated that 80 
replacement of the ectodomain of the S glycoprotein of the apathogenic IBV Beaudette strain with 81 
the same region from either of two pathogenic IBV strains, M41-CK or 4/91, resulted in two non-82 
virulent rIBVs, BeauR-M41(S) and BeauR-4/91(S), respectively. Notably, both rIBVs based on 83 
the BeauR backbone acquired the same cell tropism of that of the donor S, M41-CK or 4/91 (22, 84 
 o
n
 Septem
ber 18, 2018 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
5 
 
23). Other work demonstrated that the Beaudette S2 subunit confers the unique ability of Beaudette 85 
to replicate in African Green Monkey Kidney (Vero) cells, a continuous cell line licensed for 86 
vaccine production (24, 26). Vaccination with BeauR-M41(S) or BeauR-4/91(S) can confer 87 
protection against homologous challenge based on ciliary activity, reductions in clinical signs and 88 
viral load in the trachea at 5 days post-challenge (dpc), further demonstrating the dominant role of 89 
the S glycoprotein in inducing protective immunity (23, 25). 90 
In this study we investigated the protection conferred against homologous challenge by two rIBVs, 91 
BeauR-M41(S1) and BeauR-QX(S1), that contain S1 subunits from economically relevant strains, 92 
M41 and QX respectively, with the S2 subunit derived from BeauR. Notably both rIBVs have the 93 
advantageous ability to replicate in Vero cells (26; Bickerton et al. submitted for publication) due 94 
to the presence of the Beaudette S2 subunit. We report here on the first application of rIBV with a 95 
chimaeric S gene to be used in a vaccination trial. The rIBV BeauR-M41(S2) was also investigated 96 
in order to elucidate the relevant roles of both subunits in protective immunity. Whilst the S1 97 
subunit is considered to be immunodominant, the S2 subunit is highly conserved between strains 98 
and contains immunogenic regions (14, 27).  99 
We have shown here that vaccination with a recombinant IBV expressing a chimaeric S gene can 100 
induce a partially protective response against challenge, as assessed by viral load, cellular 101 
infiltration, clinical signs and a boost in serum antibody titres post-challenge. Vaccination with 102 
rIBV expressing homologous S1 and S2 subunits (i.e. full S gene) in the Beaudette backbone 103 
induced partial protection classified by the level of ciliary activity and presence of clinical signs 104 
following challenge with wild-type IBV. Comparison of in vitro growth characteristics shows that 105 
inclusion of a foreign S gene or a chimaeric S gene in the rIBVs does not impede replication in 106 
vitro. However, our data show that despite the ability to induce a degree of virus-specific protective 107 
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immunity, the rIBVs are hindered by limited in vivo replication and the attenuated BeauR 108 
backbone.   109 
 110 
RESULTS 111 
Characterisation of rIBV BeauR-M41(S1) and BeauR-QX(S1) for homologous protection. 112 
To determine if a single vaccination with rIBV expressing the S1 subunit of the S gene (with a 113 
Beaudette derived S2 subunit) was sufficient to induce protection against challenge with 114 
homologous pathogenic isolates of IBV, a vaccination/challenge trial was conducted with BeauR-115 
M41(S1) and BeauR-QX(S1).  No clinical signs nor loss of ciliary activity in the trachea were 116 
observed in either of the vaccinated groups following vaccination (data not shown). These results 117 
showed that replacement of the BeauR S1 gene with the S1 gene from pathogenic strains did not 118 
confer pathogenicity to the resulting BeauR-M41(S1) and BeauR-QX(S1) viruses. 119 
Three weeks after the primary inoculation, chickens were challenged with a homologous wild-type 120 
virus strain, M41-CK or QX. Clinical signs were at the highest level in the challenge control 121 
groups, with QX more pathogenic than M41-CK (Fig. 2A and 2B).  The rIBV vaccines expressing 122 
the S1 subunit did not confer full protection against clinical signs associated with IBV, although 123 
snicking and rales in the group vaccinated with QX(S1) resolved quicker than the QX challenge 124 
control (Fig. 2A and 2B).  Vaccination with BeauR-M41(S1) or BeauR-QX(S1) did not prevent 125 
the loss of ciliary activity in the trachea following challenge with the homologous wild-type virus 126 
(Table 1).   127 
To investigate the tissue tropism of the rIBVs, a range of tissues collected at 2 and 4 days post-128 
vaccination (dpv) were assessed by RT-PCR.  BeauR-M41(S1) and BeauR-QX(S1) RNA was not 129 
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detected in the conjunctiva, Harderian gland, nasal-associated lymphoid tissue (NALT) or trachea 130 
at 2 and 4 dpv (data not shown).  Histological analysis of the head-associated lymphoid tissues 131 
revealed cellular infiltrates in both the Harderian gland and the conjunctiva-associated lymphoid 132 
tissue (CALT) at 2 dpv (Fig. 3A-3D), with areas of CALT more prominent in vaccinated tissues 133 
compared to Mock (Fig. 3E). Collectively, these suggest that the recombinant vaccine viruses did 134 
infect these tissues but were no longer detectable by PCR at 2 dpv, suggesting rapid clearance from 135 
the sites of inoculation and mucosal tissues in the head-associated lymphoid tissues, exerted by a 136 
virus-specific protective immune response.   137 
To elucidate if BeauR-M41(S1) and BeauR-QX(S1) were able to confer a degree of protection 138 
against homologous challenge, evident by a reduction in viral load of infected tissues post-139 
challenge, qPCR was conducted to assess the level of viral RNA in trachea and CALT.  At 2 dpc, 140 
IBV viral RNA load in both trachea and CALT were significantly lower in the BeauR-M41(S1) 141 
vaccinated groups compared to challenge controls (Fig. 4A and 4C), but at 4 dpc the viral RNA 142 
load was only significantly lower in the CALT of the BeauR-QX(S1) vaccinated group (Fig. 4B 143 
and 4D).  Infectious viral load determined by titration of trachea tissue supernatant in TOCs, 144 
showed a reduction in infectious virions recovered from BeauR-M41(S1) and BeauR-QX(S1) 145 
vaccinated chickens, although not significant compared to corresponding wild-type controls 146 
(BeauR-M41(S1), P=0.961 and BeauR-QX(S1), P=0.999) (Fig. 4E). The wild-type control groups 147 
were the only groups to report significantly higher infectious viral loads recovered from the trachea 148 
compared to that of the Mock/Mock controls (Fig. 4E).      149 
Serum IBV-specific antibodies were assessed post-vaccination (pre-challenge) at 21 dpv and at 2, 150 
4 and 14 dpc.  Compared to the challenge control group, titres were significantly higher in the 151 
BeauR-QX(S1) vaccinated group at 2 and 4 dpc (Fig. 5A and 5B) (P<0.05 and P<0.01, 152 
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respectively).  At 14 dpc, serum titres were higher in both the BeauR-M41(S1) and BeauR-QX(S1) 153 
vaccinated groups compared to the challenge control groups, but only the QX vaccinated group 154 
was significantly higher compared to the corresponding challenge control group (Fig. 5C and 5D) 155 
(P<0.05).  For both vaccinated groups, antibody titres at 21 dpv (pre-challenge) could be classed 156 
as “borderline” positive due to being above the limits of the S/P cut-off (Fig. 5C and 5D).     157 
In summary, results from Trial 1 suggest that although vaccination of the chickens with BeauR-158 
M41(S1) and BeauR-QX(S1) did not confer complete protection against homologous challenge 159 
based on clinical signs and ciliary activity, a single vaccination of young chickens induced a 160 
partially protective virus-specific immune response as indicated by a significant reduction in viral 161 
load in trachea and CALT tissues. Higher IBV-specific serum antibody titres compared to 162 
challenge-only controls shows that vaccination with chimaeric rIBVs were able to prime the birds 163 
for challenge. Whether the lack of full protection against the loss of ciliary activity and clinical 164 
signs was due to the absence of a homologous S2 subunit or an incorrect folding of M41/QX (S1) 165 
and BeauR (S2) and therefore lower infectivity could not be answered in this specific study. 166 
Therefore, a second trial addressing the issue of whether a homologous S2 is required for 167 
protection was conducted. 168 
Relative contribution of S1 and S2 to homologous protection. In Trial 2, the rIBV used were; 169 
BeauR-M41(S), BeauR-M41(S1) and BeauR-M41(S2) (described in Fig. 1), with a similar 170 
experimental design to that of Trial 1.  No clinical signs were observed in any of the vaccinated 171 
groups after vaccination (data not shown).  Following vaccination, there was no loss of ciliary 172 
activity in the trachea, indicating the apathogenicity of the rIBVs (data not shown). In the same 173 
manner to Trial 1, at 21 dpv the chickens were challenged with M41-CK.  Clinical signs were 174 
observed until 7 dpc, BeauR-M41(S) was the only vaccinated group to show less prevalent clinical 175 
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signs post-challenge compared to the M41-CK challenge control (Fig. 6A and 6B).  There was 176 
little difference between the BeauR-M41(S1), BeauR-M41(S2) and M41-CK groups in terms of 177 
the presence and severity of clinical signs (Fig. 6A and 6B), but in the vaccinated groups clinical 178 
signs resolved more rapidly compared to the M41-CK controls.  Ciliary activity was assessed at 4 179 
dpc and the level of protection afforded were assessed according to European Pharmacopeia 180 
standards (28). The BeauR-M41(S) vaccinated group retained ~60% ciliary activity, showing an 181 
improved level of protection in comparison to groups vaccinated with BeauR-M41(S1) and 182 
BeauR-M41(S2), in which 20% protection in each group were evident (Table 2). Noteworthy, 183 
assessment on an individual bird level showed that 3 out of 5 birds in the BeauR-M41(S) were 184 
classed as “protected against ciliostasis” however, as the group average was 60% this does not 185 
translate into protection on a group level (Table 2).  186 
Viral RNA loads in the tracheas and CALTs isolated from challenged chickens were determined 187 
by qPCR to elucidate whether the S1 and S2 subunits played any further role in conferring 188 
protection.  At 2 dpc only the CALT from BeauR-M41(S) and BeauR-M41(S2) vaccinated 189 
chickens showed any significant reduction (P<0.001) in viral RNA load compared to the challenge 190 
control (Fig. 7A).  However, at 4 dpc all groups had significantly lower viral RNA loads in the 191 
CALT (Fig. 7B) (P<0.001, BeauR-M41(S) and P<0.01, BeauR-M41(S1) and BeauR-M41(S2)).  192 
Viral RNA loads in the trachea were only significantly lower at 2 dpc in BeauR-M41(S) vaccinated 193 
chickens (P<0.001, BeauR-M41(S)) and significantly lower for all vaccinated groups at 4 dpc (Fig. 194 
7C and 7D) (P<0.05, BeauR-M41(S) and BeauR-M41(S2), P<0.01, BeauR-M41(S1)).  Failure to 195 
locate the rIBVs in the head-associated lymphoid and respiratory tissues at 2 dpv in Trial 1, lead 196 
to the inclusion of the 1 dpv time-point in Trial 2.  BeauR-M41(S), BeauR-M41(S1) and BeauR-197 
M41(S2) were detected by RT-PCR in a number of the Harderian glands and tracheas isolated 198 
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from chickens at 1 dpv, however, at 2 and 4 dpv the rIBVs were mainly detected in the nasal 199 
turbinates (Table 3), suggesting rapid clearance of rIBVs from the mucosal head tissues and sites 200 
of inoculation.  Although, the titres of infectious challenge virus recovered from tracheas at 4 dpc 201 
were not significantly reduced in BeauR-M41(S), BeauR-M41(S1) and BeauR-M41(S2) 202 
vaccinated chickens compared to controls (because of the variation within each group), there was 203 
a general trend that vaccination resulted in a reduction in viral infectivity, with no detected 204 
infectious virus recovered in 4 out of 5 birds in the (S) group, 3 out of 5 in the S1 group and 1 out 205 
of 5 in the S2 group (Fig. 7E). Collectively, this shows that the chimaeric rIBVs are able to induce 206 
a degree of local protection against the replication of IBV in the trachea.   207 
To assess if the rIBVs induced humoral antibody responses following vaccination with BeauR-208 
M41(S), BeauR-M41(S1) and BeauR-M41(S2) viruses, IBV-specific serum titres were assessed 209 
at 2 and 4 dpc.  At 2 dpc, there was clear evidence of a boost in antibody titres in the BeauR-210 
M41(S) and BeauR-M41(S2) vaccinated groups (Fig. 8A), with significantly higher titres 211 
compared to Mock/M41 controls (P<0.001). IBV induced antibody titres at 2 dpc in BeauR-212 
M41(S) vaccinated chickens were higher than those from BeauR-M41(S1) and BeauR-M41(S2) 213 
vaccinated chickens across the dilution series (Fig. 8A). At 4 dpc, serum antibody titres from all 214 
vaccinated groups were significantly higher compared to the Mock/M41 titres (Fig. 8B), 215 
suggestive of a primed antibody response in the vaccinated chickens. The serum antibody titres at 216 
14 dpc indicated no significant differences between the vaccinated groups and the challenge-only 217 
controls (Fig. 8C), suggesting that a boosted response was lacking in response to challenge with 218 
wild-type virus. 219 
The virus neutralisation activity of the serum collected at 4 and 14 dpc were assessed and at 4 dpc 220 
there was no neutralisation of the virus detected (data not shown).  At 14 dpc, only serum from 221 
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BeauR-M41(S) and BeauR-M41(S1) vaccinated chickens had significantly higher neutralisation 222 
activity of the virus compared to Mock/Mock control (P=0.002 and P=0.0066, respectively; Fig. 223 
9A).  BeauR-M41(S) vaccination induced significantly higher virus neutralisation titres compared 224 
to BeauR-M41(S2) vaccination (P=0.04), whereas there was no significant difference in titres 225 
compared with serum from BeauR-M41(S1) vaccinated or Mock/M41 challenge-only group (Fig. 226 
9A). The levels of virus neutralisation activity detected were moderately positively correlated to 227 
the anti-IBV serum titres (r2= 0.5, P=0.002, Fig. 9B). 228 
Characterisation of rIBVs in vitro. Following on from the observation of differences during the 229 
in vivo vaccination trials, to elucidate whether the inclusion of a chimaeric S gene or a foreign S 230 
gene had an effect on viral replication, the replication kinetics of rIBV BeauR-M41(S), BeauR-231 
M41(S1) and BeauR-M41(S2) viruses were investigated in vitro. At 12 hpi all viruses had similar 232 
titres (Fig. 10A and 10B). This suggests that the inclusion of a foreign S gene, or a chimaeric S 233 
gene has not impeded replication in vitro in either chicken kidney cells (CKCs) derived from Valo 234 
chickens (Fig. 10A) nor CKCs derived from Rhode Island Red (RIR) birds (Fig. 10B).  Single-235 
step growth curves performed in CKCs derived from RIR birds show that over the latent period 236 
(2-8 hpi), BeauR-M41(S2) had lower virus titres compared to the other viruses, however when the 237 
exponential growth was compared there was no statistical difference between the viruses (Fig. 238 
10C). The titres of BeauR-M41(S) and BeauR-M41(S1) are similar over all time points (Fig. 10C). 239 
 240 
DISCUSSION 241 
We have previously shown that rIBVs expressing the ectodomain of the Spike protein of a 242 
pathogenic strain in the context of an apathogenic strain BeauR, could induce increased levels of 243 
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protection against homologous and partially against heterologous challenge infection. Here, we 244 
extended this work and replaced only the S1 subunit of the ectodomain of BeauR with the S1 245 
domain of M41 or QX, representing two strains that circulate in poultry flocks worldwide. These 246 
rIBVs have the advantage of being able to replicate in Vero cells, potentially allowing large scale 247 
vaccine production in cell culture rather than in embryonated eggs. In this first vaccination study, 248 
using a single dose of BeauR-M41(S1) or BeauR-QX(S1) in 1-week-old chicks, the birds were not 249 
protected against homologous challenge based on ciliary activity and clinical signs. Vaccination 250 
with BeauR-QX(S1) induced significantly higher serum titres post-challenge and the clinical signs 251 
associated with challenge virus, although present, decreased rapidly compared to unvaccinated 252 
birds challenged with QX. Together, these data show that vaccination with chimaeric rIBVs are 253 
able to induce a degree of virus-specific immunity with partial local protection in the mucosal head 254 
tissues and the primary site of replication, the trachea. 255 
In attempt to address the questions of whether a full homologous S is required for optimal folding, 256 
virus replication and protection using an apathogenic recombinant virus, a second vaccination 257 
experiment was performed. One-week-old birds were immunised once with BeauR-M41(S), 258 
BeauR-M41(S1), or BeauR-M41(S2). Replacement of the apathogenic BeauR-S1 or S2 subunits 259 
with a S1 or S2 from a pathogenic strain, allowed BeauR to remain apathogenic, suggesting that 260 
the S1 or S2 alone do not play a role in the pathogenicity of IBV.  This further expands our previous 261 
work showing that spike switching of BeauR-S with M41-S showed no effect on pathogenicity 262 
(23).  Here, vaccination of chickens with a rIBV based on a BeauR backbone expressing a full S 263 
gene from the donor serotype enhanced the level of protection afforded against tracheal ciliostasis, 264 
with 3 out of 5 birds classed as fully protected. However, when classified under European 265 
Pharmacopeia standards for assessment of IBV vaccines (28), at which 80% protection (at a group 266 
 o
n
 Septem
ber 18, 2018 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
13 
 
level) against ciliostasis is required, the BeauR-M41(S) vaccinated group was only able to confer 267 
partial protection (~60%), and therefore is still not satisfactory for the criteria used for the 268 
assessment of IBV vaccines for industrial application.  Consistent with previously published work, 269 
we show that collectively as a group the chickens vaccinated via ocular-nasal routes with BeauR-270 
M41(S) had ~60% ciliary activity remaining, a reduction in clinical signs and viral load post-271 
challenge (25). The protection seen at the trachea may potentially be improved with assessment of 272 
ciliostasis at a later time-point, as Armesto et al. (23) reported that vaccination with BeauR-4/91(S) 273 
gave ~60% ciliary activity at 4 dpc, which then improved to 90-100% at 6 dpc. In Trial 1, viral 274 
RNA load in the trachea and CALT from the S1 vaccinated groups was reduced at 2 dpc, whereas 275 
in Trial 2, all vaccinated groups had a clear significant reduction in viral RNA load at 2 and 4 dpc 276 
in trachea and CALT.  The qPCR used here is designed to detect the 5’UTR region of the genome 277 
(29) and it therefore may be detecting incomplete virions or challenge virus captured in the lumen 278 
of the trachea. To further support the viral RNA load data, infectious viral load recovered from the 279 
trachea in both Trial 1 and 2 were lower in rIBV vaccinated chickens, indicating a degree of local 280 
protection at the site of infection, which was not robust enough to completely protect against viral 281 
replication in vivo and the loss of ciliary activity. 282 
The major surface glycoprotein of coronaviruses, spike, is a type 1 glycoprotein and has two 283 
structurally distinct conformations, pre-fusion and post-fusion (30-32). In the coronavirus 284 
replication cycle the spike mediates the critical steps of receptor binding and membrane fusion. 285 
Upon binding of the S1 receptor binding domain to the host cell, an irreversible conformational 286 
switch to the post-fusion state allows the S2 subunit to fuse viral and cellular membranes, 287 
facilitating entry of the viral genome and therefore downstream viral replication (32-34). Recently, 288 
the crystal structure of the pre-fusion spike from Mouse hepatitis virus (MHV) and Human 289 
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coronavirus (HCoV HKU1) were resolved, highlighting the critical role that the interaction 290 
between the trimers of S1 and S2 plays in stabilisation of the pre-fusion conformation of spike (31, 291 
32). Here, expression of a chimaeric spike in a recombinant IBV backbone with the lack of a 292 
homologous S2 possibly resulted in conformational changes either within the S1 subunit or 293 
complete S protein, potentially affecting receptor binding and entry, but may have also altered 294 
immunogenic epitopes. The S2 subunits of BeauR shares 87% and 97% amino acid sequence 295 
similarity with QX and M41-CK, respectively, showing that there are only a few different amino 296 
acid residues between them. The interactions between S1 and S2 sub-units are critical for 297 
maintenance of conformation, recognition and efficient fusion of the spike to host cells; it has been 298 
consistently shown that even a single amino acid change within the S2 subunit of coronavirus 299 
spikes may influence the secondary structure of the overall spike or the S1 subunit (35, 36). 300 
The development of a cryo-EM structure of IBV M41 spike, highlighting the evolutionary 301 
difference between the pre-fusion spike structures of IBV compared to betacoronaviruses and 302 
alphacoronaviruses, nonetheless indicates a high degree of structurally similarity to porcine 303 
deltacoronavirus (37, 38). This structural model of pre-fusion IBV spike will significantly aid in 304 
addressing the challenges over whether (i) expression of a chimaeric spike in a rIBV backbone 305 
causes conformational changes either within the S1 subunit or complete S or (ii) it is vital that 306 
homologous “matched” S1 and S2 and their interactions are required to maintain the correct pre-307 
fusion conformation of spike, as suggested in other coronaviruses.  308 
The Beaudette strain, used here in the reverse genetics system, has an extended in vitro tropism, 309 
ability to grow in cell cultures and an apathogenic nature, making it an excellent resource for 310 
investigation of heterologous genes and growth characteristics of rIBV. During embryo passages 311 
however the Beaudette strain may have acquired mutations which are likely to contribute to its 312 
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lack of pathogenicity and restrict its in vivo tropism and replication. Replacement of the BeauR S1 313 
or S2 with corresponding subunits from a pathogenic strain did not indicate a significant 314 
impairment of in vitro growth of the viruses in comparison to the BeauR virus, showing no 315 
indication that BeauR-M41(S1) and BeauR-M41(S2) were unable to enter the cells, fuse with cell 316 
membranes or failed to replicate in vitro. Nevertheless, the lack of full protection afforded by 317 
BeauR rIBVs against wild-type challenge and the limited in vivo replication, strongly suggest that 318 
attenuations have occurred in genes playing an essential role in replication and these are negatively 319 
impacting upon its suitability as a vaccine vector. Development of an alternative, less attenuated 320 
backbone for expression of heterologous genes in rIBVs may promote the development of these 321 
live attenuated vaccines for the control of IBV.  322 
Expression of the IBV S1 subunit alone has been shown to induce virus neutralising antibodies, 323 
albeit often requiring repeated vaccination (8, 10).  Here, immunisation of chickens with rIBVs 324 
based on the Beaudette backbone expressing either M41 S or chimaeric S1/S2 induced virus 325 
neutralising antibodies, however the Mock/M41 serum also had a degree of neutralising activity. 326 
BeauR-M41(S) vaccinated chickens had significantly higher virus neutralising titres compared to 327 
BeauR-M41(S2) group but there was no statistical difference with the BeauR-M41(S1) group, 328 
showing that following a single vaccination with rIBV expressing M41(S1) neutralising antibodies 329 
are induced.  330 
Live attenuated vaccines against IBV need to induce a good level of mucosal immunity with local 331 
tracheal and cell-mediated immunity also playing an important role in prevention of IBV infection 332 
(39, 40, 42). As discussed earlier, the BeauR backbone is impeded by poor in vivo replication and 333 
the lack of protection shown against ciliostasis indicates that there is a poor level of local immunity 334 
induced in the trachea by vaccination with BeauR rIBVs. Cytotoxic responses can also play a key 335 
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role in the early control of IBV as indicated by previous studies showing; NK cell activation (41), 336 
IBV-specific cytotoxic T-cell lymphocyte (CTL) activity of splenocytes isolated from IBV-337 
infected chickens (42) and higher CTL proportions in respiratory tissues following IBV infection 338 
(43). Cellular infiltrates in the head-associated lymphoid tissues as well as a reduction in viral load 339 
in the trachea and CALT also implies that the rIBVs infected the chickens and suggests a possible 340 
role for the cell-mediated response.  However, as we were unable to consistently detect the 341 
recombinant S1 viruses at 2 dpv, it raises possibilities that the viruses were either rapidly cleared 342 
from the tissues, replicate poorly at these sites of inoculation or have limited replication in a few 343 
cells which are below detectable limits of the assays. In the BeauR-M41(S) vaccinated group, over 344 
50% of the chickens were positive for vaccine virus as assessed by RT-PCR, in the Harderian 345 
gland and nasal turbinates at 1 and 2 dpv, respectively.  The primary site of IBV infection is thought 346 
to be the ciliated epithelium lining the trachea, however following ocular-nasal vaccination the 347 
virus has been detected in the nasal turbinates (44) and Harderian gland (45).  348 
One possible explanation for poor protection of ciliary activity afforded by the recombinant S1 349 
viruses could be that we only administered one single vaccine dose to the SPF chicks.  Previous 350 
studies using baculovirus expressed IBV recombinant proteins or IBV purified proteins have 351 
required multiple injections to achieve a degree of protection in SPF chickens (10, 17).  There is 352 
also evidence of an impaired humoral response in young chicks with regards to IBV vaccination; 353 
vaccination of 1-day and 7-day-old chicks showed a delay in both systemic and local IgA and IgG 354 
levels compared to vaccination of older chicks (14, 21 or 28-day-old) (46).  Here, in an attempt to 355 
improve the protection against respiratory signs and ciliostasis with the recombinant S1 viruses, a 356 
prime/boost approach may aid in overcoming these potential issues.       357 
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 In summary, we have previously generated recombinant IBV based on a BeauR backbone 358 
expressing a heterologous S1 from M41 or QX, and in the present study we have shown that a 359 
single vaccination in young chicks with these rIBVs although not adequate to completely prevent 360 
ciliostasis and clinical signs, they can induce a degree of virus-specific protective immunity. This 361 
was characterised by reduction in viral load recovered from trachea and CALT, cellular 362 
infiltrations at head mucosal and inoculation sites, higher serum anti-titres in vaccinated groups 363 
and induction of virus neutralising activity. Vaccination with BeauR-M41(S), despite expressing 364 
the homologous full S to attempt to overcome any issues with heterologous S1 and S2 subunits 365 
and suboptimal folding, only induce a partially protection against the loss of ciliary activity. As in 366 
vitro growth characteristics shows that inclusion of a foreign S gene or a chimaeric S gene in the 367 
rIBVs does not impede replication in vitro it suggests that the attenuated Beaudette backbone has 368 
hindered the in vivo replication of these rIBVs and to improve protection, multiple vaccinations or 369 
an alternative backbone may be required.  370 
 371 
MATERIALS AND METHODS 372 
Ethics statement. All animal experimental protocols were carried out in strict accordance with the 373 
UK Home Office guidelines and under licence granted for experiments involving regulated 374 
procedures on animals protected under the UK Animals (Scientific Procedures) Act 1986. The 375 
experiments were performed in The Pirbright Institute (TPI) Home Office licensed (X24684464) 376 
experimental animal house facilities and were approved by TPI animal welfare and ethical review 377 
committee under the terms of reference HO-ERP-01-1.  Trial 1 used SPF Rhode Island Red (RIR) 378 
chickens obtained from TPI Poultry Production Unit in Compton.  Trial 2 used the same chicken 379 
breed but obtained from The National Avian Research Facility in Edinburgh. 380 
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Cells and viruses. Tracheal organ cultures (TOCs) were prepared from 19-day-old SPF RIR 381 
chicken embryos (47-49). Primary Chicken Kidney (CK) cells were prepared by The Central 382 
Services Unit, TPI from kidneys extracted from either 2 to 3-week-old SPF RIR chickens or 2-383 
week-old SPF derived Valo chickens (49). The pathogenic M41 strain (50) used in this study had 384 
previously been adapted in CK cells to produce M41-CK (Accession number X04722) (25). The 385 
pathogenic strain, QX (QX L1148 strain, Accession number KY933090) (51), was donated by 386 
Prof. Richard Jones, University of Liverpool.  The rIBVs BeauR-M41(S), BeauR-M41(S1), 387 
BeauR-M41(S2) and BeauR-QX(S1) used herein are described in a schematic illustration (Fig. 1) 388 
and constructed using the backbone of Beau-R,  which is the molecular clone of Beau-CK 389 
(Accession number AJ311317) (21, 26). All isolates of IBV and rIBV were propagated in 10-day-390 
old RIR SPF embryonated eggs. Allantoic fluid was clarified by low speed centrifugation, 24 to 391 
48 hours post infection (hpi). Titrations to determine virus infectivity were either performed in 392 
TOCs as described by (25), or in CK cells (49); titres are expressed as 50% (median) ciliostatic 393 
doses (CD50) per ml or plaque forming unit (PFU) per ml, respectively.  394 
Analysis of growth kinetics in CK cells. Confluent CK cells seeded in either 6-well or 12-well 395 
plates were inoculated with 104 PFU rIBV or IBV for multi-step growth curves or 105 PFU rIBV 396 
or IBV for single-step growth curves in 0.5 ml serum-free N,N-Bis(2-hydroxyethyl)-397 
2aminoethanesulphonic acid (BES) medium and incubated for 1 h at 37oC, 5 % CO2. Cells were 398 
washed with phosphate buffered saline a (PBSa) to remove residual virus and 2 ml of serum-free 399 
BES medium was added per well. Extracellular virus was harvested at defined intervals and 400 
assayed by titration in CK cells.  401 
Experimental design of in vivo vaccination/challenge trials. SPF RIR chickens were housed in 402 
positive-pressure, HEPA-filtered isolation rooms in which each group was housed in a separate 403 
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room. In two separate experiments, birds were randomly divided into 5 groups of 30 birds for Trial 404 
1 and 5 groups of 40 birds for Trial 2.   Eight-day-old chicks were inoculated (classified as primary 405 
inoculation) with 105 PFU of BeauR-M41(S1) or BeauR-QX(S1) (Trial 1) or 104 PFU BeauR-406 
M41(S), BeauR-M41(S1) or BeauR-M41(S2) (Trial 2) in a total of 0.1 ml of PBS via conjunctival 407 
(eye drop) and intranasal routes.  A challenge dose, equal to the primary inoculation, 105 PFU 408 
(Trial 1) and 104 PFU (Trial 2) of the corresponding wild-type viruses were administered in the 409 
same manner 21 days after the primary inoculation to the appropriate groups. Of note, the IBV QX 410 
strain used here could not be propagated in CK cells, so a CD50 dose of 102.73 was used. Mock-411 
infected controls were inoculated via the same route with 0.1 ml of PBS and mock/challenge 412 
control groups were inoculated with 0.1 ml PBS and challenged with the same dose of wild-type 413 
virus.  Birds were euthanised by cervical dislocation at specific times post-infection and a panel of 414 
tissues sampled to allow for downstream analysis.  Blood samples were collected and processed 415 
for the collection of serum. Clinical signs used to determine pathogenicity were snicking, rales and 416 
ciliary activity of the trachea (a bird was considered protected if 50% or more ciliary activity was 417 
retained in 9 out of 10 tracheal rings, this must be in 80% of the group) (28, 52).  418 
Isolation of tissues: Virus isolation and ciliostasis assay. Tissues collected were divided into 419 
two parts; one part was stabilised in RNAlater® (Ambion) for RNA extraction and the other in 420 
20% sucrose/PBS (0.22µM filtered) at 4oC overnight before snap freezing in OCT (Thermo 421 
Scientific) for histology. Tissues collected included: Harderian gland, CALT, NALT and trachea.  422 
Tissues were removed at 2 and 4 days post-vaccination (dpv), and at 2, 4 and 14 dpc.  Tracheas 423 
were removed from five randomly selected chickens from each group at 4 dpv and 4 dpc for 424 
assessment of ciliary activity as described previously (25). Part of the trachea and CALT tissues 425 
were stored in PBS for virus isolation. 426 
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Detection of viral RNA.  For virus isolation and RNA extraction, tissues stored in PBS and RNA-427 
later, respectively, were freeze-thawed and homogenised using the TissueLyser II (Qiagen), as 428 
described in (23).  Total RNA was isolated using the RNeasy® Mini Kit and DNase treated 429 
following manufacturer’s instructions (Qiagen). cDNA was synthesised from 1µg of tRNA using 430 
Superscript IV Reverse Transcriptase (Life Technologies) with a random oligo primer as per 431 
manufacturer’s instructions.  To quantify infectious viral load in trachea, tissue derived supernatant 432 
was titrated in TOCs. To determine whether infectious virus was present, 10-day-old SPF 433 
embryonated eggs were inoculated with 100 µl Allantoic fluid, at 24 – 48 hpi they were assessed 434 
for viral presence by RT-PCR using primers specific for the 3’UTR, as described by (53). For 435 
quantification of viral load, qPCR was performed using the Taqman Universal PCR Master Mix 436 
(Applied Biosystems) with primers and probes specific to the 5’ UTR region, as described by (29).  437 
Serial dilutions of M41 cDNA (generated from 1µg tRNA) were included to generate a standard 438 
curve and data expressed in terms of the cycle threshold (Ct) value, were normalised using the Ct 439 
value of 28S cDNA product for the same sample (54). 440 
Infectious Bronchitis Virus ELISA. Serum samples collected at 21 dpv (pre-challenge), 2, 4 and 441 
14 dpc were assayed with the commercial IDEXX IBV antibody test kit (IDEXX laboratories).  To 442 
determine the end-point titre the serum samples were two-fold serially diluted in the range 1:20 – 443 
1:2560 prior to incubation.  After sample incubation, the remaining steps were followed directly 444 
according to the manufacturer’s instructions.  The sample/positive (S/P) ratio was determined by 445 
the following equation = (Mean sample – Mean Kit Negative)/(Mean Kit positive – Mean Kit 446 
Negative). S/P ratios above 0.2 were considered to be positive for IBV antibodies.  Polyclonal 447 
chicken serum raised against M41 and QX serum were included on each independent test plate 448 
(GD Animal Health). 449 
 o
n
 Septem
ber 18, 2018 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
21 
 
Immunocytochemistry. For fluorescent microscopy, cryostat sections (5µm) were fixed in 450 
acetone, washed in PBS, and blocked for 1 h at RT with 10% normal goat serum and 0.5% bovine 451 
serum albumin in PBS (blocking buffer). Slides were washed and incubated for 1 h with optimally 452 
diluted primary antibodies (anti-Bu-1 (clone AV-20, AbD Serotec), anti-CD8α (clone 3-298, AbD 453 
Serotec); anti-CD8β (clone EP42, AbD Serotec) and anti-CSF1R (55) or isotype controls, all 454 
diluted in blocking buffer.  Sections were washed and incubated with an Alexa Fluor 488-labeled 455 
goat anti-mouse IgG1/IgG2a or Alexa Fluor 568-labeled goat anti-mouse IgG1/IgG2b according to 456 
the appropriate isotype, diluted in blocking buffer for 1 h. Nuclei were visualized using DAPI 457 
(Invitrogen). Images were captured with a Leica DMLB fluorescence microscope with a coupled 458 
device digital camera and analysed using ImageJ analysis software. For light microscopy, cryostat 459 
sections (5µm) were fixed in acetone and stained with Harris’ Haematoxylin (Sigma-Aldrich) and 460 
1% Eosin (Sigma-Aldrich).  Sections were dehydrated through graded ethanols and xylene and 461 
mounted in a xylene-based medium (DePex, Gurr-BDH Chemicals).  Images were captured with 462 
a Hamamatsu Nano-zoomer-XR digital slide scanner. 463 
Analysis of neutralising antibody. Virus neutralisation tests were performed by GD Animal 464 
Health (56).  Briefly, two-fold serial dilutions of serum were made in a 1:1 mixture of Medium-465 
199 and Ham’s F10 in 96-well plates.  To each well an equal volume of CEK cells (in medium 466 
supplemented with 10% FCS) were added.  After culture with M41 for 3-4 days at 37oC with 5% 467 
CO2, cell monolayers were examined for CPE. All individual titres were expressed as log2 of the 468 
reciprocal of the highest serum dilution that showed complete inhibition of CPE. 469 
Statistical analyses.  Viral load qPCR data were tested for normality through residual plots and 470 
the difference between the mean corrected 40-Ct values were statistically evaluated by the 471 
parametric one-way ANOVA test adjusted for post-hoc analysis, Tukey’s pairwise comparison. 472 
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Serum antibody levels, viral isolation titres, ciliary activity and virus neutralisation titres were 473 
tested for normality and non-parametric analyses conducted.  Differences between the groups were 474 
statistically evaluated by the non-parametric Kruskal-Wallis test adjusted for post-hoc analysis, 475 
Mann Whitney U pairwise comparison.  The relationship between anti-IBV serum and virus 476 
neutralisation titres were compared by Spearman rank correlation analysis. Analysis of the viral 477 
growth curves was conducted by fitting a polynomial curve to the exponential phase of viral growth 478 
(57), growth rates were then compared between groups by the non-parametric Kruskal-Wallis test 479 
adjusted for post hoc analysis. For all statistical analyses, P values of less than 0.05 were 480 
considered significant.  All statistical analysis was conducted in MiniTab version 17 or GraphPad 481 
Prism 7. 482 
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Figure legends 659 
Figure 1. Design of rIBV constructs. Schematic of wild type BeauR and rIBV genomes generated 660 
by reverse genetics to display homologous spike genes in Beaudette backbone. The rIBVs 661 
generated expressed either the S1 and/or S2 ectodomain and transmembrane domain (TM) from 662 
M41 and QX wild-type virus; with M41 derived genes represented by red boxes and QX derived 663 
genes represented by green boxes. In all rIBVs the Beaudette backbone is represented by solid blue 664 
boxes and the endodomain (E) of S2 from Beaudette is represented by shaded blue boxes. *BeauR-665 
M41(S) displays the full ectodomain of M41 spike, as previously described (22). 666 
 667 
Figure 2. Assessment of clinical signs associated with BeauR-M41(S1) and BeauR-QX(S1) 668 
infected chickens following challenge with M41-CK or QX.  (A) Snicking and (B) Rales (n=10-669 
20 per group).    670 
 671 
Figure 3. Cellular infiltrates of head associated lymphoid tissues following vaccination with 672 
BeauR-M41(S1) and BeauR-QX(S1).  (A and B) Harderian gland at 2dpv (C-E) CALT tissue at 673 
2dpv. (A and C) Cryosections were stained with monoclonal antibodies to detect CSF-1R+ (red) 674 
and CD8β+ (green) cells or (B and D) to detect Bu-1+ (green) and CD8α+ (red) cells.Nuclei were 675 
labelled with DAPI (blue). The scale bars represent 50 µm. (E) H and E stained cryosections of 676 
the lower conjunctiva, inset images depict CALT regions detected in (A) BeauR-M41(S), (B) 677 
BeauR-QX(S1) tissues which were not clearly evident in (C) Mock lower conjunctivas. The scale 678 
bars represent 250 µm. Representative images are shown for all.  679 
 680 
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Figure 4. Viral load in CALT and Trachea in BeauR-M41(S1) and BeauR-QX(S1) vaccinated 681 
chickens following challenge with M41-CK or QX. (A-D). Relative viral RNA load (expressed as 682 
corrected 40-Ct) at specific time-points: (A and C) 2 dpc, (B and D) 4 dpc. (E) Infectious viral load 683 
titres in trachea at 4 dpc. Data points are shown as individual animals and lines represent mean and 684 
standard error of mean (SEM). Statistically significant differences between groups are highlighted; 685 
*, P <0.05; **, P < 0.01.  686 
 687 
Figure 5. Measurement of serum anti-IBV titres of BeauR-M41(S1) and BeauR-QX(S1) 688 
vaccinated groups. Serum titres were assessed by commercial ELISA at (A) 2 dpc, (B) 4 dpc, (C) 689 
M41 groups at 14 dpc and (D) QX groups at 14 dpc. Pre-challenge titres (i.e. 21dpv) are included 690 
in (C) and (D). The mean S/P (±SD) from each group (n=5-10) and includes four technical 691 
replicates/animal. Dashed line shows the cut-off for positive samples (S/P=0.2). Solid bars denote 692 
a trend in statistical significance across dilutions in comparisons with Mock/challenge only group 693 
e.g. BeauR-QX(S1)/QX compared to Mock/QX and BeauR-M41(S1)/M41 compared to 694 
Mock/M41; *, P<0.05. 695 
 696 
Figure 6. Assessment of clinical signs associated with BeauR-M41(S), BeauR-M41(S1) and 697 
BeauR-M41(S2) vaccination following challenge with M41-CK. (A) Snicking and (B) rales 698 
(n=10-20 per group).  699 
 700 
Figure 7. Viral load in CALT and trachea in BeauR-M41(S), BeauR-M41(S1) and BeauR-701 
M41(S2) vaccinated chickens following challenge with M41-CK. (A-D) Relative viral RNA load 702 
(expressed as corrected 40-Ct) at (A and C) 2 dpc and (B and D) 4 dpc. (E) Infectious viral load 703 
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titres in trachea (4 dpc). Data points are shown as individual animals and lines represent mean 704 
(±SEM). Statistically significant differences between groups are highlighted; *, P<0.05; **, 705 
P<0.01; ***, P<0.001. 706 
 707 
Figure 8. Measurement of serum anti-IBV titres of BeauR-M41(S), BeauR-M41(S1) and BeauR-708 
M41(S2) vaccinated groups. Serum titres were assessed by commercial ELISA at (A) 2 dpc, (B) 4 709 
dpc and (C) 14 dpc. The mean S/P ratio (±SEM) from each group (n=10) includes four technical 710 
replicates/animal.  Dashed line shows the cut-off for positive samples (S/P=0.2). Solid bars denote 711 
a trend in statistical significance across dilutions in comparisons with Mock/challenge only group 712 
e.g. BeauR-M41(S), BeauR-M41(S1) and BeauR-M41(S2) compared to Mock/M41; *, P<0.05.  713 
 714 
Figure 9. Measurement of virus neutralisation antibody titres of BeauR-M41(S), BeauR-M41(S1) 715 
and BeauR-M41(S2) vaccinated and Mock groups at 14 dpc.  (A) Virus neutralisation titres were 716 
determined by titration of serum in CK cells. Virus neutralisation titres expressed as log2 of the 717 
reciprocal of the highest serum dilution that showed complete inhibition of CPE (n=5 or 10). Lines 718 
represent mean (±SEM). Statistically significant differences between groups are highlighted; *, 719 
P<0.05; **, P<0.01; ***, P<0.001). (B) Relationship between virus neutralisation activity and 14 720 
dpc anti-IBV serum titres. Data points represent the S/P ratios from individual serum samples 721 
(n=39) plotted against virus neutralisation titres, compared by Spearman rank correlation analysis.  722 
 723 
Figure 10. Comparison of the growth curves of BeauR-M41(S), BeauR-M41(S1) and BeauR-724 
M41(S2). (A) Multi-step growth curve in chicken kidney (CK) cells derived from Valo chickens, 725 
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(B) 24 h growth curve and (C) single-step 12 h growth curves in CK cells derived from RIR 726 
chickens.  Supernatant was harvested at various time-points post-infection and titres of progeny 727 
virus were determined by a plaque titration assay on CK cells. Data points represent mean of three 728 
independent experiments and error bars represent SEM. 729 
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Table 1. Assessment of protection against ciliostasis associated with BeauR-M41(S1) and BeauR-
QX(S1) vaccination following challenge with M41-CK or QX. 
Vaccination/Challenge Mean ciliary 
activity (±SD)1 
Number of birds with 
90% ciliary activity2 
Percentage of 
group protected3 
Mock/Mock 92% (±8.2%) 5/5 N/A 
Mock/M41 2% (±1.4%) 0/5 0% 
BeauR-M41(S1)/M41 9% (±16.3%) 0/5 0% 
Mock/QX 1% (±0%) 0/5 0% 
BeauR-QX(S1)/QX 1% (±1.4%) 0/5 0% 
1Mean ciliary activity per group calculated from ciliostasis scores for 10 tracheal rings per individual bird 
using formula = ((total ciliostasis score of tracheal rings)/40)*100. 
2Ciliary activity assessed according to European Pharmacopeia standards (27) where bird is deemed 
protected against ciliostasis if no fewer than 9 out of 10 tracheal rings per bird showed normal ciliary 
activity (>50% ciliary activity retained). 
3The vaccine is considered to be efficacious at conferring protection against ciliostasis when 80% or more 
of the birds in a group were protected. 
 
 
Table 2. Assessment of protection against ciliostasis associated with BeauR-M41(S), BeauR-
M41(S1) and BeauR-M41(S2) vaccination following challenge with M41-CK.   
Vaccination/Challenge Mean ciliary 
activity (±SD)1 
Number of birds with 
90% ciliary activity2 
Percentage of 
group protected3 
Mock/Mock 96% (±5.2%) 5/5 N/A 
Mock/M41 0% (±0%) 0/5 0% 
BeauR-M41(S)/M41 65% (±36.2%) 3/5 60% 
BeauR-M41(S1)/M41 19% (±33%) 1/5 20% 
BeauR-M41(S2)/M41 23% (±43.4%) 1/5 20% 
1Mean ciliary activity per group calculated from ciliostasis scores for 10 tracheal rings per individual bird 
using formula = ((total ciliostasis score of tracheal rings)/40)*100. 
2Ciliary activity assessed according to European Pharmacopeia standards (27) where bird is deemed 
protected against ciliostasis if no fewer than 9 out of 10 tracheal rings per bird showed normal ciliary 
activity (>50% ciliary activity retained). 
3The vaccine is considered to be efficacious at conferring protection against ciliostasis when 80% or more 
of the birds in a group were protected. 
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Table 3. Detection of IBV-derived RNA by RT-PCR in head associated lymphoid tissues and 
trachea samples following vaccination with BeauR-M41(S), BeauR-M41(S1) and BeauR-
M41(S2).   
Vaccination 
Days post-
vaccination 
Number of virus positive tissues per group 
Harderian gland Trachea Nasal turbinates 
Mock 
1 
 
0/5 0/5 N/A 
BeauR-M41(S) 3/5 0/5 N/A 
BeauR-M41(S1) 1/5 0/5 N/A 
BeauR-M41(S2) 1/5 2/5 N/A 
Mock 
2 
0/5 0/5 0/5 
BeauR-M41(S) 1/5 0/5 3/5 
BeauR-M41(S1) 0/5 0/5 3/5 
BeauR-M41(S2) 0/5 0/5 2/5 
Mock 
4 
0/5 0/5 0/5 
BeauR-M41(S) 3/5 0/5 2/5 
BeauR-M41(S1) 1/5 0/5 2/5 
BeauR-M41(S2) 1/5 2/5 3/5 
The results are depicted as “number of positive samples/number of birds per group” (total of 5 
birds/group).  All positive results were confirmed by sequencing of PCR products (data not shown).   
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